<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01281787</url>
  </required_header>
  <id_info>
    <org_study_id>IEO S365/407</org_study_id>
    <secondary_id>2007-003856-12</secondary_id>
    <nct_id>NCT01281787</nct_id>
  </id_info>
  <brief_title>PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer</brief_title>
  <acronym>PRESAGE</acronym>
  <official_title>Prevention of Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether prophylactic treatment with metoprolol or losartan
      is able to reduce the incidence of atrial fibrillation (AF) in patients undergoing thoracic
      surgery for lung cancer, showing elevated plasma levels in NT probrain natriuretic peptide
      (NT-proBNP), measured in the perioperative period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postoperative atrial fibrillation is one of the most common complication after thoracic
      surgery for lung cancer, with an incidence ranging from 8 to 20% after lobectomy and up to
      42% after pneumonectomy.

      In a recent study we demonstrated that a high perioperative plasma levels of NT-proBNP is
      able to identify patients at risk for AF (incidence of 65%).

      It has also been demonstrated that the renin-angiotensin system may play an important role in
      the pathophysiology of atrial fibrillation and that angiotensin converting enzyme inhibitors
      (ACEI) and angiotensin II receptor blockers (ARBs) are able to prevent atrial fibrillation in
      patients with heart failure, after myocardial infarction, in hypertensive patients and after
      electrical cardioversion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of postoperative atrial fibrillation</measure>
    <time_frame>up to 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of NT-proBNP in the days following the start of treatment and post surgery duration of hospital stay</measure>
    <time_frame>up to 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>angiotensin II-receptor blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no preventive treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>beta-adrenergic antagonist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>SELOKEN, LOPRESOR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>LORTAAN, NEOLOTAN, LOSAPREX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes with age â‰¥ 18 years

          -  Thoracic surgery for lung cancer

          -  Evidence of elevated perioperative NT-proBNP

          -  Written informed consent

        Exclusion Criteria:

          -  Hypersensitivity and / or intolerance to metoprolol or losartan

          -  History of heart failure

          -  Left ventricular ejection fraction &lt;50% measured by echocardiographic techniques
             (Simpson rule)

          -  Permanent atrial fibrillation

          -  Antiarrhythmic therapy

          -  Current therapy with beta-blockers, angiotensin II receptor blockers and
             angiotensin-converting enzyme inhibitors

          -  Systolic blood pressure &lt;95 mmHg

          -  Pregnant and lactating women

        Additional exclusion criteria for therapy with beta-blocker:

          -  History of sick sinus syndrome, evidence of AV-block grade II or greater

          -  Heart rate &lt;65 b / m

          -  History of bronchial asthma, severe bronchopneumopathy, evidence of bronchospasm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Cardinale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FAP= post-surgery atrial fibrillation</keyword>
  <keyword>ACEI= angiotensin converting enzyme-inhibitors</keyword>
  <keyword>ARBs= angiotensin II receptor blockers</keyword>
  <keyword>NT-proBNP= brain natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

